DDInter1588 DDInter1376
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tadalafil
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Ribociclib may lead to a major life threatening interaction when taken with Enzalutamide
Ribociclib may lead to a major life threatening interaction when taken with Lurbinectedin